iBio's AI Platform Targets GPCR Antibody Discovery Gap

iBio is using generative AI to engineer antigens that guide antibody discovery toward specific epitopes, aiming to close the "trust gap" between AI's promise and real-world drug development costs. The company has integrated its AI platform with experimental validation pipelines, citing its IBIO-600 program as reaching clinic approval in roughly two years from inception. Key case studies include breaking immune tolerance in latent TGF-beta 1 and Activin E targets, where engineered epitope mimics produced immune responses comparable to full-length protein immunization. iBio is also developing IBIO-610, a potential first-in-class Activin E antibody for obesity indications.